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Abstract
Much of Alzheimer disease (AD) research has been traditionally based on the
use of animals, which have been extensively applied in an effort to both improve
our understanding of the pathophysiological mechanisms of the disease and to test
novel therapeutic approaches. However, decades of such research have not effectively
translated into substantial therapeutic success for human patients. Here we critically
discuss these issues in order to determine how existing human-based methods can
be applied to study AD pathology and develop novel therapeutics. These methods,
which include patient-derived cells, computational analysis and models, together with
large-scale epidemiological studies represent novel and exciting tools to enhance and
forward AD research. In particular, these methods are helping advance AD research by
contributing multifactorial and multidimensional perspectives, especially considering
the crucial role played by lifestyle risk factors in the determination of AD risk. In
addition to research techniques, we also consider related pitfalls and flaws in the
current research funding system. Conversely, we identify encouraging new trends
in research and government policy. In light of these new research directions, we
provide recommendations regarding prioritization of research funding. The goal of this
document is to stimulate scientific and public discussion on the need to explore new
avenues in AD research, considering outcome and ethics as core principles to reliably
judge traditional research efforts and eventually undertake new research strategies.
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Introduction

vascular risk factors and the risk of dementia associated
with heart failure, stroke, or atrial fibrillation over the
course of thirty years [10].
Much of the traditional AD research has been
based on the use of animal models, often transgenic (Tg)
and inbred mice, in an effort to recapitulate genetic and
pathological traits of human disease [11]. However, Tg
animals, despite presenting several of the typical AD
traits, such as amyloid β (Aβ) formation, neuritic plaques,
neurofibrillary tangles (NFT), gliosis, synaptic alterations
and signs of neurodegeneration, do not develop the
clinicopathological complexities of human AD [12-15].
Moreover, treatments that seem to work in such models
have not translated to humans [11, 16-18]. This indicates
the existence of a clear disconnection between the (animal)
model and the human condition [17] that is not taken into
sufficient account by investigators. Another issue with
animal models is that they might also be generating false
negative data, leading to the exclusion of compounds from
clinical studies that could be effective in humans.
An examination of current methodological
approaches, suggests a bias in the peer-review process
in favor of using these animal models versus alternative
approaches. Specifically, the number of projects - and
funds - based on animal models supported by the U.S.
National Institutes of Health (NIH) over the last eight
years is much higher than the number of research
projects focused on the use of human-based models and
methods (e.g., human-derived (stem) cells, neuroimaging,
computational models, prevention, clinical studies,
etc.) (Figure 1). Although efforts such as the National
Alzheimer’s Project Act — which has dramatically
boosted resources for AD and related dementias (ADRD)
research — are beginning to prioritize human relevant
approaches and attempting to address the multifactorial
and multi-etiology of dementia there remains a strong
bias towards animal research approaches . This bias can
be seen throughout reports and recommendations in the
strong linking of “animal research” with “basic research”.
For example, in the 2016 update of draft prioritized
recommendations of the ADRD, the implementation of
the recommendation from Session 6, Focus Area 1: Basic
Mechanisms and Experimental Models - “Develop next
generation experimental models and translational methods
for VCID (vascular contributions to cognitive impairment
and dementia)” six out of nine recommendations explicitly
call for the development of of animal models [19]. In
conflating the concepts of animal research and basic
research there is a failure to recognize the important
development that basic laboratory research is increasingly
being performed entirely without the use of animals.
Indeed, without the critical acknowledgement of the
failure of past animal paradigms and the promise of new
approaches, new attempts at making progress in basic AD
research will be severely hampered.
Beyond laboratory models, several lifestyle-related

On April 17th 2015 the Physicians Committee for
Responsible Medicine (http://www.pcrm.org/) held a
roundtable with expert researchers on Alzheimer disease
(AD) and human-based research approaches from the
United Stated and the United Kingdom, to discuss why
and how the AD research community should adopt humanbased research strategies to overcome the increasing
prevalence of AD in the 21st century. The major goals
of the roundtable were: (1) to discuss the relevance
of human-based models and tools for investigating
AD pathophysiology at multiple levels of biological
complexity, taking human relevance into account; (2)
to formulate strategic recommendations as potential
guidelines for determining research funding priorities
in the field of AD research. In the present document we
describe the major discussion outcomes of that meeting.
We also reflect on how these recommendations fit in with
current, quickly evolving, scientific and public policy
efforts.
It is important to note that roundtable participants
sometimes expressed different opinions regarding the
discussed topics. While some felt that the first step should
be to reduce animal models, others felt that current
techniques already offer vast, powerful and unexplored
pathways to study AD, and that sufficient alternatives
already exist to fully proceed with human-based research.
However, all participants agreed that there is now a range
of new techniques and research directions that have been
under-explored and need to be supported through changes
in public funding and research priorities.

The AD research paradigm is
failing: main facts supporting
this premise
Alzheimer disease (AD) represents the most
common cause of dementia, accounting for 50-75% of all
dementia cases [1, 2]. The number of persons affected by
AD in the United States is expected to almost triple by
2050, reaching 13.8 million [3]. Despite intense research
efforts, the mechanisms of action of both protective and
causative factors for AD are still not clearly understood.
In the last ten years no new drugs have been released and
existing drugs only stabilize symptoms temporarily in
some patients, but do not slow progression of the disease
[4, 5]. This defeat is reflected by the dramatically high
clinical failure rate (99.6%), which is the highest among
biomedical research fields [6-8]. One bright prospect
is that the occurrence of dementia has recently been
reported to be stabilizing in Western Europe, but this has
been primarily attributed to preventative approaches and
improvements in living conditions [9]. Analogously, the
Framingham Heart Study has reported a decline of both
www.impactjournals.com/oncotarget
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Figure 1: Bar graphs reporting the absolute numbers of AD-related projects focused on the use of animal models
(black bars) vs projects accounting only for human-relevant models/methods (white bars). A. and relative funding B.,

provided by the NIH from fiscal year (FY) 2007 to 2014. Analysis has been done using http://projectreporter.nih.gov/reporter.cfm (as of
July 6th 2015), project search was limited to ‘project terms’. List of applied keywords per category: AD & animal models: Alzheimer AND
(“primate” OR “primates” OR “monkey” OR “monkeys” OR “macaca” OR “macaque” OR “marmoset” OR “vervet” OR “cercopithecus”
OR “cynomolgus” OR “tamarin” OR “dog” OR “dogs” OR “canine” OR “canines” OR “canis” OR “feline” OR “felines” OR “felis” OR
“guinea” OR “rabbit” OR “rabbits” OR “mouse” OR “mice” OR “porcine” OR “pig” OR “pigs” OR “ovine” OR “sheep” OR “rattus” OR
“rat” OR “rats” OR “mus” OR “mice” OR “mouse” OR “mammal” OR “fish” OR “zebrafish” OR “hamster” OR “rodent” OR “animal
model” OR “animals” OR “animal” OR “xenopus” OR “caenorhabditis elegans” OR “c. elegans” OR “drosophila melanogaster” OR
“drosophila” OR “lamprey”). AD & human models: Alzheimer AND “human” AND (“stem cells” OR “induced pluripotent stem cells”
OR “iPS” OR “imaging” OR “PET” OR “MRI” OR “computational” OR “prevention” OR “preventive strategy” OR “clinical study” OR
“clinical” OR “clinical trial” OR “patient”) NOT (“primate” OR “primates” OR “monkey” OR “monkeys” OR “macaca” OR “macaque”
OR “marmoset” OR “vervet” OR “cercopithecus” OR “cynomolgus” OR “tamarin” OR “dog” OR “dogs” OR “canine” OR “canines” OR
“canis” OR “feline” OR “felines” OR “felis” OR “guinea” OR “rabbit” OR “rabbits” OR “mouse” OR “mice” OR “porcine” OR “pig”
OR “pigs” OR “ovine” OR “sheep” OR “rattus” OR “rat” OR “rats” OR “mus” OR “mice” OR “mouse” OR “mammal” OR “fish” OR
“zebrafish” OR “hamster” OR “rodent” OR “animal model” OR “animals” OR “animal” OR “xenopus” OR “caenorhabditis elegans” OR
“c. elegans” OR “drosophila melanogaster” OR “drosophila” OR “lamprey”)
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Table 1: Human-based studies, models and readouts suitable for AD research
Human-based models/tools

Characteristics and applicability

To assess the complex interrelations of risk factors and
influences including: environmental triggers,
Epidemiological
studies, ameliorating
genetic
susceptibility,
sex, gender, diet, physical activity, corandomized clinical trials
occuring conditions (e.g., diabetes), cognitive engagement,
social interactions and other cultural factors.
Healthy and diseased brain tissues with short post-mortem
intervals, standardized preparation, accessible samples
and data. To account for patient heterogeneity and study
Human ex vivo tissue
cellular and structural pathologies. To aid in the validation
of biomarkers and to refine analysis of factors involved in
disease progression
To study human brain anatomy through 2D and 3D images
in vivo and ex vivo studies. To refine AD diagnosis and
Neuroimaging techniques (e.g., in
uncover
early markers of disease, understand longitudinal
MRI, PET, MRI tractography)
structural development of AD, assessment of treatment
effects, construction of brain atlas/connectome
To define kinetics and dynamics of environmental factors
Connectomics, PBPK, and PD (e.g., compounds, nutrients) exposure and to predict their
studies, IVIVE,
long term effects in relation to AD. To assess the efficacy of
compounds for AD treatment
To investigate tissue complexity, assess effects of possible
Microfluidics/organ-on-chip
therapeutic compounds.
Patient-derived samples: CSF, To define early biomarkers of AD, to generate xeno-free
blood/plasma,
fibroblasts, iPSCs.
lymphocytes
3D models, organoid systems (e.g., To mimic physiology of the brain tissues. Suitable depending
iPSCs, NSCs)
on the research goals.
Glutamatergic & cholinergic neurons and astrocytes. iPSCneurons show AD phenotypic traits consistent with the Aβ
tau hypotheses after limited time in culture (e.g., elevated Aβ
increased levels of p-tau) and responsiveness to
Early, familial and late-onset production,
β
and
γ
secretase
AD patient-iPSCs and their Genome-editing inhibitors.
technologies (e.g., ZFN, TALENs, and
differentiated
functional CRISPR/Cas9) can
be used to add, disrupt or modify the
derivatives (2D and 3D)
sequence of specific genes related to AD, measure their
impact on human iPSC-derived neurons and, ideally, design
patient tailored treatments.
To identify disease pathways & drug targets, & assess
therapeutic compounds.
To define bio-metals distribution and concentrations in the
Synchrotron x-ray fluorescence human brain affected in AD. To characterize the metalloimaging
relationship of plaques and tangles, volumetric reductions in
brain regions in AD.
Omics:
transcriptomics,
proteomics,
lipidomics,
assess signaling pathways, epigenetic, genetic mutations,
metabolomics,
exposomics, To
nutrigenomics,
nutrigenetics, gene expression & lifetime exposures
genomics, epigenomics
Can be applied at any of the above levels to investigate the
causal relations, illuminate underlying mechanisms and to
Computational modeling
help predict outcomes of interventions in relation to AD at
single and multiple scales

Biological complexity
level
Population, individual

Individual, whole brain

Individual, whole brain

Individual, whole brain
Tissue, whole brain
Tissue
Cell,
Organoids

Networks,

Cell,
Networks

Assemblies,

Multi-scale: Sub-cellular
to Individual, whole
brain
Protein, gene, individual
Ranges from gene
to neural population
dynamics

Abbreviations: CSF, cerebrospinal fluid; iPSCs, induced pluripotent stem cells; NSCs, neural stem cells; MRI, magnetic
resonance imaging; PET, positron emission tomography; PBPK, physiologically based pharmacokinetics; IVIVE, in vitroin vivo extrapolation; PD, pharmacodynamics; ZFN, zinc-finger-nucleases; TALENs, transcription activator-like effector
nucleases; CRISPR/Cas9, clustered regularly-interspaced short palindromic repeats/CRISPR-associated protein-9 nucleases.
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as already envisioned in toxicology [46] and proposed
for AD research [17]. Within this new framework it is
becoming increasingly possible to not only determine the
effects of an exposure to a given compound (for instance,
pollutants possibly implicated in the onset of AD) but
also to investigate how these effects are induced [47,
48]. Defining which signaling pathways are perturbed
at early stages of AD (i.e., the AD-related pathways)
might help predict long-term effects and sequelae. For
this reason, multiscale AOPs should become the core
of the new paradigm in AD research. Investigating ADrelated multiscale AOPs could allow researchers to link
environmental and genetic causes with outcomes at
individual/body level [17].
A number of cellular in vitro models of AD and
human-based methods can already take into account
different levels of biological complexity (Table 1). For
example, iPSCs have been widely applied in AD research
[49-53] and can be used to: (i) assess clinical candidate
drugs on human brain cell types; (ii) conduct phenotypic
screening of compounds that modulate or normalize
disease phenotype; (iii) conduct target-based screening if
candidate genes are identified; (iv) compare geneticallydiverse panels; or (v) select or stratify participants of
clinical trials based on their genetic backgrounds and/or
phenotypic traits.
Moreover, human-based intervention trials focused
on nutrition, physical activity, and cognitive training
are particularly relevant to preventing AD and cognitive
decline. These trials have proven to be the most effective
strategies to reduce AD symptoms [20, 25, 26, 54-59].
In order to stimulate the creation of multifactorial
approaches to AD, global efforts have been made to
improve access and discussion online for researchers.
In recent years, common platforms, such as CLIR
(Collaborative Laboratory Integrated Reports), developed
at the Mayo Clinic (https://clir.mayo.edu/), have been
shown suitable to create groups of interest and propose
multidisciplinary team approaches, allowing comparisons
among different sub-populations, different ages and
different treatments. At the clinical level, databases, such
as the Laboratory of Neuroimaging - Image Data Archive
(LONI-IDA), provide user access to de-identified data
from positron emission tomography (PET), magnetic
resonance imaging (MRI), cognitive data sets and
biomarkers. These interfaces represent a large step forward
in maximizing the impact of these data.
As alternatives to the use of traditional mammalian
species, some non-mammalian/non-vertebrate models,
such as Dictyostelium discoideum, have also be applied
to undertake new directions in basic research [60, 61]
and define the role of previously unexplored proteins/
molecules. Taking into account their biological limitations
(e.g., they cannot effectively be used to mimic the largescale anatomical and behavioral aspects of an aging
human brain), these non-mammalian models are relatively

risk factors have been shown to play key roles in the
onset and progression of AD, yet research support in
theses domains remains disproportionately low, with
only a 3.4% of average annual funding supported by the
National Institute on Aging (NIA) for prevention in 20102012 [20]. Although advancing age is clearly considered
the main risk factor for developing AD [21-23], nutritional
factors [24], low levels of physical activity [25, 26],
reduced cognitive stimulation [27], socioeconomic status
and educational attainment [28-30] are all directly related
to AD risk. Furthermore, poor sleep quality [31-33] which
is known to positively correlate to early Aβ deposition
[34, 35], air pollution [36], smoking [37], intake of metals
[38-40], pesticides and insecticides [41, 42] as well as
metabolic-related dysfunctions [43, 44] have all been
described as possible risk factors.
These data indicate that - rather than an independent
health condition - AD should be reinterpreted as a complex
multifactorial syndrome. Understanding this complexity
is clearly critical for designing intervention strategies
aimed at preventing or ameliorating early symptoms of
AD. Despite this knowledge and massive potential social
impact, longitudinal clinical studies focused on prevention
are very poorly supported in the U.S. (only ~ 7%-9% of
the $30 billion NIH total discretionary budget) [20]. For
all these reasons there is an urgent need to rethink current
research funding strategies to directly target human
relevance and disease causation.

Addressing human relevance
in AD research with the use
of alternatives to animal
experiments
Recent developments have brought about a
staggering array of research approaches that are offering
bold new ways to study human brain aging and are
yielding profuse and meaningful human relevant data.
These techniques include: (1) several human-based models
focused on the use of patient-derived cells, such as induced
pluripotent stem cells (iPSCs) and neuronal and glial
cultures, (2) multiple ‘omic’ technologies (e.g., genomics,
proteomics, lipidomics, transcriptomics, metabolomics,
etc.) resulting from overall analyses of biological samples
by high-throughput analytical approaches and databases,
(3) computational analytical approaches and (4) novel
neuroimaging readouts [17, 18, 45].
Given the need to integrate the huge amount of
incoming data, comprehensive multi-scale and systems
biology approaches are becoming fundamentally
important. These approaches must take into account all
the different levels of biological complexity (including
population, individual, organ/tissue, cellular, protein,
and gene level), thereby allowing for the elucidation
of disease-related adverse outcome pathways (AOPs),
www.impactjournals.com/oncotarget
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Table 2: Limitations of alternative models and methods and strategies to overcome these limitations
Human-based models/tools

Limitations

Strategies to address limitations
Comprehensive assessment of multiple behaviors and
risk factors and complex multivariate analyses to address
conjoint confounding and effect modification.
Inability to determine causality due to potential Application of machine learning and other techniques
capable of non-linear and high-dimensional pattern
Epidemiological studies, randomized multiple interacting and confounding factors
recognition in large data sets.
clinical trials
Difficult to compare studies designed according to Possibility to create multi-center collaborations, taking
different inclusion/exclusion criteria
advantage of common platforms
Multiple intervention studies to test treatment effects in
different types of populations
Creation of multi-center collaborations to standardize
methods & optimize distribution: e.g., 2-3 nationwide
brain banks centers of excellence, with 24/7 autopsy
services, short postmortem delays (2-3 hours maximum)
and with standardized neuropathological protocols.
Digitize neuropathology finds using standardized methods
and creating an open-access database for additional
analysis.
costs; sometimes weak correlations between Consider large-scale studies to improve correlations
Neuroimaging techniques (e.g., MRI, High
measures and clinical manifestations; sometimes between imaging measurements and clinical
PET, MRI tractography)
difficult to quantify
manifestations
Synchrotron x ray fluorescence
Requires ex vivo or post mortem brain tissue
Integrate this technology with other neuroimaging tools
imaging
Some limitations with regard to transport and diffusion Increase investment in research and development.
Microfluidics/organ-on-chip
of nutrients and oxygen; individual organs, kept in Complement these technologies with neuroimaging data
isolation
and/or other omics data sets
Integrate 3D models with 2D models depending on
3D models (e.g., iPSCs, NPCs)
Not applicable for all purposes
applications and research goals
Generating high-quality iPSCs is expensive and time Cost is dropping over time; several entities (e.g., CIRM,
consuming; a limited number of AD iPSC lines have NYSCF, etc.) are funding the development of hundreds of
been generated and thoroughly characterized so far
iPSC lines from AD patients
Possibility to create co-culture systems with human
microglial cells.
They might be not fully representative of the complex Genome-editing technologies can be applied to create
physiology of the brain and/or of AD pathophysiology mutations related to the AD genetics, measure their impact
on patient iPSC-derived neurons and design patient
tailored treatments.
Different reprogramming and QCs have been used, so Several entities (e.g., CIRM, NYSCF, etc.) could
comparisons between labs are difficult to make at this standardize reprogramming methods allowing inter-lab
time
comparisons
Challenges with regard to penetrance, cell purity, Need to harmonize QC standards, which would be more
degree and type of differentiated cells generated from feasible with the participations of dedicated entities
iPSCs
Storage and analytic methods are often not
preventing inter-lab comparisons
Patient-derived samples: CSF, blood/ standardized,
preserved brain tissues and long postmortem
plasma, fibroblasts, and postmortem Poorly
delays
AD and control brain tissues
Samples are often not readily available for test for
reproducibility and validation

Traditional reprogramming methods (e.g., integrating Develop and adopt xeno-free techniques with nonlentiviruses) and xeno-contamination might have integrating reprogramming vectors
affected the phenotype of the lines
AD
patient-iPSCs
and
their Epigenetic signatures of the somatic cell of origin Possibility to directly reprogram fibroblasts into neurons
differentiated functional derivatives
might be retained in the reprogrammed iPSCs
Possibility to reprogram post-mitotic neurons and frozen
(NB: evidence that epigenetic traits get lost upon long brain tissue samples into iPSCs (to retain the neuronal
term culture)
epigenetic and pathologic background)
iPSCs metabolic profile has not been investigated Define QC metrics to establish metabolic features of
enough (which has special relevance in AD research) iPSCs
Use AD brain tissues as benchmark models to define
metrics suitable to assess neuronal and pathological
Still not clear how long iPSC-derived neurons should QC
of differentiated iPSCs.
be kept in culture in order to mimic late-onset AD features
of aging-related genes (e.g., progerin)
neurons and tissue pathophysiology; possible issues Overexpression
help model AD in a dish.
with the loss of aging-related transcriptional signatures might
Direct conversion of aging donors' fibroblasts into
and features.
neurons (iNs) can help retain aging-related transcriptional
signatures.
2D and 3D iPSC cultures might be characterized by Define QC metrics to establish features of 2D vs. 3D iPSC
different biological/cellular/molecular features and cultures
generate different responses
Not clear if AD-derived fibroblasts might be proven
as suitable as their reprogrammed counterparts (i.e. Define QC metrics to establish features of AD-derived
iPSCs) to define molecular/cellular features of AD fibroblasts vs AD-derived reprogrammed iPSCs
(e.g., metabolic profiles)
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Consider their suitability for basic research effort; less
time consuming and less expensive than traditional
phylogenetically distant from humans than
animal models
Non-mammalian/invertebrate models More
mammalian species; might lead to intermediate valiof AD
Investigate directly in human ex vivo tissues/cultures
dation steps in mammalian (non-human) species
(rather than animals) to assess preclinical data (applying
microdosing analysis)
to establish dedicated consortia with a multiPBPK, PD and IVIVE are currently applied mainly in Possibility
disciplinary approach (e.g., combining medical research
PBPK and PD studies, IVIVE
toxicology.
and toxicology expertise).

Connectomics still in early development. Resolution
low. Very large data sets.
Connectomics, computational analy- too
Computational models are often restricted to simply
sis and modeling
mimicking observed phenomena and have no predictive value.
Various other omics: transcriptomics,
proteomics, lipidomics metaboloHigh costs
mics, exposomics, nutrigenomics,
nutrigenetics, genomics, epigenomics

Develop techniques to study both individual and large
cohorts necessary to recognize significant patterns.
Increases in resolution, computational power and largescale analysis algorithms are all rapidly improving.
Encourage move to foundational computational simulations that explore the basic effects of cellular, network
and system factors in aging and dementia. Use to
elucidate and predict previously unrecognized changes in
anatomy, physiology and cognition.
Costs of analysis are reducing. Possibility to establish
dedicated consortia with a multi-disciplinary approach
(e.g., combining molecular biology and biostatics
expertise)

Abbreviations: CSF, cerebrospinal fluid; iPSCs, induced pluripotent stem cells; QC, quality control; NSCs, neural
stem cells; MRI, magnetic resonance imaging; PET, positron emission tomography; PBPK, physiologically based
pharmacokinetic; IVIVE, in vitro-in vivo extrapolation; PD, pharmacodynamics

AD-derived iPSC models

easy to handle, cost effective, and can be manipulated to
express AD-related human genes/proteins [61]. providing
innovative approaches to research in this area.
The availability of a range of approaches and
collaborative tools is an important development in AD
research. Obviously, the use of a given model should be
driven by the specific research objectives, whether they
be basic research or translational. In light of the fact that
a unique model suitable to tackle all aspects of AD does
not (and may never) exist, different models might be
suitable to cover the many different aspects of the disease
depending on the level and mechanism being investigated.
For this reason, in an effort to gather a global picture of the
environmental/lifestyle risk factors, the etiopathological
mechanisms of the disease and define possible preventive,
intervention and pharmaceutical strategies, the creation
of a multidisciplinary team approach in AD research,
combining different expertise, should be mandatory.
In line with this, some research initiatives have been
undertaken in an effort to define correlations among Aβ
formation, neuroanatomy, cognitive and lifestyle factors
[62, 63].

With specific regard to iPSC-derived models of
AD, it is generally recognized that generating highquality iPSC lines is still expensive and time consuming.
In addition, only a limited number of AD iPSC-derived
lines have been generated and thoroughly characterized
so far. These AD-related iPSC studies have used different
programming and quality control methods, as well
a variety of somatic cell types. These differences in
protocol make inter-laboratory comparisons difficult at
this time. Moreover, the reprogramming mechanism used
to generate older iPSC lines, are often based on the use of
integrating lentiviruses and retroviruses, which may have
caused insertional mutagenesis [64, 65]. Many approaches
remain xeno-contaminated. For this reason, to minimize
these issues, current and future reprogramming methods
should aim to be xeno-free and based on the use of nonintegrating reprogramming vectors or entirely vector-free
approaches.
Nevertheless, the iPSC approach holds enormous
potentials and the rapidly expanding research field is
already tackling these limitations. For example, the
production cost is progressively dropping, and several
entities, such as the California Institute for Regenerative
Medicine (CIRM, https://www.cirm.ca.gov/) and the New
York Stem Cell Foundation (NYSCF, http://nyscf.org/) are
currently funding the development of hundreds of iPSC
lines from both early- and late-onset AD patients that will
be available globally at low cost to investigators. It will
now be important to generate dedicated and accessible
bio-banks for the collection and distribution of AD
patient-derived fibroblasts or peripheral blood cells for
reprogramming purposes, accounting for both late- and
early-onset AD, mild cognitive impairment, and healthy

Limitations
of
alternative
approaches and strategies to
overcome these limitations
Despite the great potential of new human-based
approaches and non-mammalian models, their broad
applicability and reliability is currently hampered by
some limitations. It is essential to clearly recognize these
constraints and define strategies to overcome them (Table
2).
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allowing inter-laboratory comparisons, as already
envisioned and practiced in toxicology studies [74].
Furthermore, there are some challenges with
regard to penetrance, cell purity, degree and type of
differentiated cells that can be generated from iPSCs
that need to be taken into account when developing new
models. In terms of the future directions of iPSCs in AD,
greater consideration to the metabolic profile would be
advantageous. The majority of studies published so far
have not extensively investigated the iPSC metabolic
profile; however, several lines of evidence indicate that
AD should be studied as a complex systemic/metabolic
dysfunction, correlated to metabolic syndrome [43],
hypometabolism, oxidative stress, and modifications of
the glucose-fatty acid cycle [75].
Beyond issues of epigenetic memory and
metabolism, it remains unclear how long iPSC-derived
neurons should be kept in culture in order to mimic the
development of late-onset AD neuronal cells and tissue
pathophysiology [76]. In general, modeling aging and
neurodegenerative disease, like AD, in differentiated
human neurons, such as those derived from AD patient
iPSCs, can be a challenging task. Often neuronal cells
cultured in vitro do not retain the aging-associated
transcriptional profile and phenotype, which represents
a major issue when modeling late-onset disorders, such
as late-onset AD. There are some possible ways to “age”
human neurons in a dish. In particular, the overexpression
of the premature aging-related gene s, such as progerin,
has been shown suitable to model Parkinson’s disease
in iPSCs and might be possibly applicable also for ADiPSCs [77]. Alternatively, the direct conversion of aging
donors’ fibroblasts into neurons (namedcalled induced
neurons, or iNs), avoiding cells reprogramming toward
the an embryonic phenotype, has been shown promiseing;
iNs were found to retain an aging-related transcriptional
signature (i.e., decline of the nuclear transport receptor
RanBP17) when compared to iPSCs and their neuronal
derivatives [78].
Additionally, genome-editing technologies, such
as the zinc-finger-nucleases (ZFN), the transcription
activator-like effector nucleases (TALENs), and the
clustered regularly-interspaced short palindromic repeats/
CRISPR-associated protein-9 nucleases (CRISPR/Cas9)
can now be used to overcome variability in human
genomes. Although still in development, these genomeediting technologies can already be used to add, disrupt
or modify the sequence of specific genes related to AD
and measure their impact on human iPSC-derived neurons
[79]. In particular, these nucleases can induce guided
DNA breaks, which can be repaired by homologous
recombination with a donor vector carrying a desired point
mutation or gene, in order to better model the disease in
vitro and, ideally, design patient tailored treatments [8082].
Moreover, even as researchers are using cell lines

elderly donors. These samples should be made available
to the scientific community whenever required to facilitate
inter-laboratory reproducibility, data validation and outline
correlations between patients’ clinical history and patientrelated cellular and molecular data sets, which might help
develop novel therapies. In particular, the collection of
late-onset, sporadic AD patient-derived fibroblasts for
the generation of late-onset AD iPSCs will be critical in
providing insight into late-onset AD pathology, which
represents the majority of AD cases (~95%), as compared
to early-onset AD (representing ~5% of all AD cases)
[23, 66]. These collection efforts should pay particular
attention to the language of the informed consent forms
used in donor recruitment in order to ensure patient
protection as well as the broadest possible use of the
samples by both in academic and commercial research and
clinical usersapplications.
Several aspects of the generation of iPSCs as well as
their use in studying AD include the “epigenetic memory”,
the types of reprogrammed cells used for studying
the etiology of AD, and the ability of iPSCs to mimic
AD pathophysiology. With regards to this “epigenetic
memory” phenomenon, there is evidence that the
epigenetic signatures of the somatic cells of origin might
be retained in the reprogrammed iPSCs. As a consequence,
iPSCs might preferentially generate derivatives of the
donor somatic cell type [67, 68], inadvertently skewing
results. Possible strategies to overcome this limitation
might be to directly reprogram fibroblasts into nervous
system cell types [69, 70] or, in order to retain the
epigenetic background of neuronal cells, to reprogram
post-mitotic neurons into iPSCs [71]. iPSCs have been
successfully obtained by reprogramming frozen noncryoprotected dural tissue samples (stored at −80°C for
up to 11 years), which allowed for generating iPSCs with
confirmed pathology even from AD patients with rare
genetic variants [72]. Nevertheless, there is evidence that
iPSCs lose epigenetic traits during long term culture [73],
which might be considered either as a positive aspect (as
the epigenetic memory of somatic cells of origin might be
mitigated) or a negative aspect (in light of the fact that AD
patient epigenetic signatures might also be lost over time).
Additionally, it is also unclear whether ADderived fibroblasts might be proven as suitable as their
reprogrammed iPSC counterparts to define some of the
molecular/cellular features of AD. For instance, using
AD patient-derived fibroblasts or other cell types, such as
peripheral blood mononuclear cells, might be sufficient
to detail some AD-related genetic, epigenetic and/or
metabolic features, avoiding all the reprogramming steps
and the overall time consuming neuronal differentiation
process. For all these reasons, establishing appropriate
quality control metrics, accounting for gene expression
analyses and quantifications of protein/biomarker levels
will help define the expandability of an iPSC model
for a given purpose and harmonize data interpretations,
www.impactjournals.com/oncotarget
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to address the complexities of developing a robust twodimensional in vitro model for AD research, others
are taking it a step further by working towards threedimensional iPSC cultures. This is important because twodimensional cultures of iPSCs seem to be characterized by
considerably different biological, cellular, and molecular
features as compared with their three-dimensional
counterparts [51]. The implications of the differences
in responses upon exposure to potential therapeutic
compounds in two-dimensional versus three-dimensional
models still need to be elucidated and their biological
relevance assessed. Despite these limitations and open
questions the added dimension provides an entirely new
platform to investigate pathology and therapeutics (Table
2).

human-based organ-on-chip systems, could also be applied
for pre-clinical drug discovery.
One approach that has been suggested is to validate
data obtained in non-mammalian models in a small number
of animals before moving to human tissues/cultures or
clinical trials, thereby contributing to a reduction of the
use of animals, according to the 3Rs principle envisioned
in toxicology and biomedical research [85]. However, it
should also be considered that intermediate validation
steps in non-human mammals might generate false
negative results, possibly invalidating results that might
actually be proven valuable in human settings. Moreover,
the assumption that non-mammalian species require
intermediate validation steps in mammalian non-human
models before translating obtained data into humans
largely remains unquestioned. However, data obtained
in non-mammalian and non-animal models can be
validated directly and more effectively in human ex vivo
tissues/cultures and/or postmortem tissue. This is already
being done for some rare diseases, using microdosing
analyses [86]. Most importantly, the rapidly expanding
availability of direct human assays, imaging and clinical
data collection techniques is increasingly rendering animal
models of all scales unnecessary.

Microfluidics/organ-on-chip systems
Beyond iPSCs models, microfluidics/organ-onchip systems have been created in an effort to simulate
in vitro human organ and tissue biology and function.
These models combine different cell types in specific
3D culture systems [83, 84] and might be useful to test
novel therapeutic compounds in human physiological-like
systems. However, despite their potential applicability,
these technologies are still in their infancy and require
further validation. Additionally, these models, regardless
of their level of optimization, remain fundamentally
disembodied and thus cannot capture the full complexity
and physiological function of a living organism. For this
reason, direct clinical studies, including neuroimaging
data and various omics data sets, that incorporate the full
richness of human cognitive, environmental and social
interactions will be required to complement and interpret
information derived from these in vitro models (Table 2).

Post-mortem AD brain tissues
Post-mortem AD brain tissues are important
biological resources for AD research, from which the
major AD therapies were discovered [87]. It is also critical
as a validation resource with which to assess discoveries
from cell culture and animal models. They represent an
invaluable resource to conduct neuropathology studies,
spanning from morphology, connectivity, cellular,
molecular and genome perspectives. Moreover, as clinical
studies of AD attempt to discover earlier and more
sensitive biomarkers, neuropathology studies remain the
key reference for validation [88].
However, brain tissue samples are often of
suboptimal quality, due to long postmortem delays
and inappropriate postmortem handling and storage.
High quality brain tissue from normal control subjects
is particularly scarce.
Some aspects of protein
function, phosphorylation [89], RNA integrity and the
aforementioned epigenetic modifications are strongly
altered by postmortem delay, freeze-thaw cycles and
even by freezing itself [90]. For these reasons, much of
the currently available brain tissue, while being useful to
conduct morphological studies and assess robust disease
biomarkers, may be unsuitable for many molecular studies
[91, 92]. Nevertheless, microRNA analysis of AD-affected
temporal lobe neocortical tissues collected in short postmortem interval of about 1 hour can provide important
starting points for examining specific AD alterations [93].
It has to be considered that limited availability
of post-mortem tissue and differing collection and

Non-mammalian models of AD
Non-mammalian/invertebrate models of AD (e.g.,
Dictyostelium discoideum, Drosophila melanogaster,
etc.) were previously judged poorly relevant from a
biological standpoint and for this reason less worthy of
funding compared to mammalian species phylogenetically
closer to humans (Table 2). Nevertheless, it’s worthwhile
considering the limited “return on investment” that
has been gained after extensively funding translational
research projects focused on the use of traditional
mammalian models, in particular mice. The overreliance on the use of animals, together with the lack of
implementation and optimization of human-based models,
have contributed to the current clinical attrition rate in AD
translational research [6, 8, 16].
Although non-mammalian species can be used
to define basic disease mechanisms, human-based cell
models, such as AD-iPSC neuronal cell cultures and
www.impactjournals.com/oncotarget
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preservation protocols make projects requiring very large
subject numbers, as well as inter-laboratory replication
studies difficult or impossible to perform. For these
reasons, the creation of multi-center collaborations
and bio-banks would greatly increase the ability of
researchers to make the most of these resources (Table
2). However, it would be counter-productive to simply
replicate existing brain bank networks, such as those of
the NIA Alzheimer’s Disease Centers (https://www.nia.
nih.gov/alzheimers/alzheimers-disease-research-centers)
or BrainNet Europe (http://www.brainnet-europe.org/)
as these have not been able to rapidly and systematically
provide autopsies or sufficient numbers of normal control
brains. A more targeted approach would be to provide
proportionately greater funding to a small number of
specialized centers, allowing them to meet these critical
needs. These centers should allow a streamlined system
of sharing, improve timing of distribution, increase
the quality of the available materials, harmonize tissue
collection standards and provide better correlations
between the pathology and neuroimaging patient data.
A more ambitious, yet potential ground-breaking step
for neuropathological approaches would be to digitize
research data and make them openly available along with
detailed tissue collection and analysis protocols. A model
for this could be the Alzheimer’s Disease Neuroimaging
Initiative (ADNI), which provides in-depth information
in their neuroimaging, biomarkers and genetics data
collected from large multicenter collaborations [94]. This
level of sharing and standardization would maximize the
usage of these precious tissue resources and accelerate the
improvement of neuropathologic approaches by increasing
interactions between investigators.

the complex data sets to improve quantification of
imaging features. Despite current limitations, even
existing technologies represent essential tools to support
human-relevant AD research approaches, and significant
extension of large-scale clinical studies using current
techniques should be encouraged to help improve
correlations between imaging measurements and clinical
manifestations (Table 2).

‘Omics’ technologies and computational models
Despite their relatively high costs, highthroughput technologies, such as proteomics, lipidomics,
metabolomics, epigenomics, and genomics, are currently
applied to define the molecular mechanisms underlying
AD pathogenesis [106-111].
Additionally, computational models, such as in
vitro-in vivo extrapolation (IVIVE), physiologically based
pharmacokinetic (PBPK), and pharmacodynamics (PD)
modeling, are currently applied in the field of toxicology
and regulatory testing, but might be suitable to define
kinetics and dynamics of compound exposure, predict
their long term effects in relation to AD [47, 48, 112], and
assess therapeutic potential of novel compounds for AD
treatment [113-115].
While these technologies are still under development
and require further optimization, establishing dedicated
consortia with a multi-disciplinary approach aimed at
combining medical research with toxicology expertise
might prove a winning strategy to speed the drug
discovery process (Table 2). More broadly, computational
approaches allow for unprecedented mining of data across
levels. Similarly, beyond just data mining, computational
simulations can explore the correlations and underlying
mechanisms at levels ranging from the molecular
to cellular to network, and even social scale. These
simulation techniques offer great promise but remain
largely underused.

Neuroimaging
Novel in vivo imaging readouts, such as PET and
ultra-high-field MRI are currently available to diagnose
AD [95, 96] and have been successfully applied to assess
in vivo the effects of specific nutritional interventions [5456]. Importantly, neuroimaging readouts have been critical
to discover commonalities of neuroanatomical features
shared by AD, type-2 diabetes and the metabolic syndrome
[45, 97-99], pathologies that have been shown to be highly
interconnected [100-102]. Moreover, human connectomics
enabled by techniques such as MRI tractography, allows
for the reconstruction of 3D neuronal networks, brain
anatomy, and AD-related neuroanatomical modifications
[103-105].
As is the case with many new approaches, future
neuroimaging technologies will need to overcome the
sometimes prohibitively expensive development and
operational costs. In addition, researchers will need to
improve the clarity of the identification of correlations
between retrieved measures and AD-related clinical
manifestations, as well as devise methods to deal with
www.impactjournals.com/oncotarget

Need to prioritize human
relevant research and explore
alternative research avenues
Taking into account “human relevance” when
addressing AD research efforts, funding agencies need to
implement strategies that will encourage the use of these
human-based models for AD research. The implementation
of human-based methods will also contribute to minimize
the use of sentient beings in biomedical research, as
advocated by the NIH [116] and the public [117].
To this aim, requests for applications (RFAs)
focused on the use of explicitly xeno-free human-based
models and novel high-throughput technologies should
be created. In particular, considering the potential of AD
patient-derived iPSCs, study sections should include
39008
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experts in the iPSC and reprogramming field, competent in
evaluating research proposals focused on the use of iPSC
models for AD.
Additionally, expansion of existing and creation
of new centralized and open bio-banks providing iPSC
lines and/or high quality post-mortem tissues should
be encouraged and incentivized, allowing large scale
distribution of biological samples to research institutes
when needed. While entities distributing both healthy
controls- and AD patients-derived iPSCs are already
in place in Europe, the U.S. and Japan, iPSC lines are
rarely fully characterized by providing entire genomic,
epigenomic and patient phenotype data sets [118]. For this
reason, efforts to assimilate best practice should be taken
into account [118]. Interestingly, CIRM has recognized the
value such genetic information adds to an iPSC line and
released in early 2016 a RFA (DISC3.1) to characterize all
3000 lines in its repository. Additionally, pre-competitive
and collaborative centralized distribution of iPSCs would
help to increase biological sample quality and would allow
for the creation of harmonized quality control standards
for the use, characterization, handling and storage of
biological material. Developing such guidance will
accelerate inter-laboratory data comparison and validation.
Again, consent forms need to allow such sharing.
Moreover, considering the important role
played by lifestyle and environmental factors and the
relevance of prevention to reduce the burden of AD
[9], as also commented in the Leon Thal Symposium
proceedings [119, 120], specific RFAs should be created
to encourage investigation of early phenotypic traits
of neurodegeneration and the implication of multiple
networks (or “human disease pathways”) in neuronal
failure at early stages of the disease. Amongst these
networks, research on mitochondrial dysfunction, known
to be an early event in AD progression [121-123], should
be emphasized.
Learning from failure and ethics should be
encouraged as a general attitude in research. Current
and previous research efforts to study AD pathology in
animal models and identify effective drug targets have
not led to significant and effective prevention or disease
modification in humans, so new avenues should be
explored. In this regard, even re-evaluating the validity of
traditional AD “gold standards” (i.e. the main diagnostic
biomarkers of AD), such as presence of Aβ plaques and
NFT, might help to hypothesize new therapeutic strategies.
In particular, both Aβ and NFT are known to often appear
early in time and, according to novel hypotheses, might
actually not be considered as causative of AD but rather
a result of AD pathology, which is often characterized by
neuroinflammation as well as hypometabolism [43, 75,
124]. In this regard, negative results in science are not
given enough consideration, frequently leading to their
suppression during publication. However, negative results
are crucial to establishing limitations of current research
www.impactjournals.com/oncotarget

models [125], and defining the need for new research
avenues.
The creation of pre-competitive consortia to judge
the suitability of new models would be highly relevant.
In this regard, pharmaceutical companies have shown
a willingness to abandon obsolete models, investing
resources in new human-derived paradigms involving
pre-competitive consortia, such as the Cardiac Safety
Research Consortium (http://cardiac-safety.org), the
FDA’s Critical Path Initiative (http://www.fda.gov/
ScienceResearch/SpecialTopics/CriticalPathInitiative/
ucm076689.htm), TransCelerate BioPharma (http://www.
transceleratebiopharmainc.com), the international Serious
Adverse Event Consortium (http://www.saeconsortium.
org/) and larger international consortia, such as the
Structural Genomics Consortium (http://www.thesgc.
org). Analogously, in Europe, the EU commission has
allocated 1BN euro into pre-competitive consortia
(e.g., the Innovative Medicines Initiative is EU’s largest
public-private initiative, http://www.imi.europa.eu/).
Thus, the paradigm shift to create more human-relevant
standards for validation of translational research should be
stimulated at all stakeholder levels.
Moreover, considering the relevance of prevention,
it would be necessary to increase current research budgets
allotted to preventive medical research and also to
increase expertise in the field of education and nutrition in
correlation to neurology.

Recommendations to guide new
funding strategies
While it is important to provide appropriate
funding to support research and speed the discovery
process [126], currently available resources should
also be better allocated, shifting the focus to prevention
strategies with human relevance and to the use of humanbased research methods, such as patient-derived iPSCs,
computational methods, advanced brain imaging methods,
epidemiological studies and human focused non-animal
models. Given the important knowledge we already have
regarding lifestyle-related factors (e.g., diet, exercise,
environmental exposure, etc.), we recommend that public
education and policy should be ramped up considerably
with special attention to those who may contest these
recommendation (e.g., fast food industry).
Considering the multi-dimensional nature of
AD pathology, we believe that the time is ripe for a
reevaluation of the current definitions of aging, cognition,
and their relationship to a variety of biological, social,
and environmental variables. Instead of examining a
single variable or biomarker at a time, as has often been
done in the past, it would be worthwhile to consider the
interconnected implications of several genetic, epigenetic,
morphological, environmental, behavioral and social
factors in the onset and consolidation of AD.
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Table 3: List of recommendations to guide new funding strategies
Recommendations
Implement funding for the production and
distribution of AD patient-derived
R1 centralized
cells (e.g., fibroblasts, peripheral blood cells,
iPSCs)

Comments
Consider establishing NIH-funded centers to provide investigators with patient-derived cells and already reprogrammed
iPSCs. However, this might be proven unnecessary if other
entities, such as CIRM and NYSFC, will do this on their own
Current biomarkers measure levels of Aβ (in CSF), and levels
of phospho-tau and total tau (in CSF). In this regard, neuroimAllocate funding for research proposals aim- aging technologies by means of MRI and PET (FDG-PET and
R2 ing at defining & validating early biomarkers amyloid imaging) are particularly suitable to allow early detecof AD
tion of AD and assess therapeutic efficacy in vivo. Develop and
validate additional portable and non-invasive techniques that
can identify predictive biomarkers.
Despite the fact that the majority of AD cases are late-onset,
Allocate more funding to research projects
the current number of NIH funded active projects focused on
R3 focusing on the most prevalent late-onset/spo- the late-onset/sporadic AD is lower than the number of projects
radic AD
on early-onset and familial AD (81 vs 182, as of July 6th 2015.
Data retrieved from http://projectreporter.nih.gov/reporter.cfm )
would be relevant considering the need for expensive high
funding to centers conducting omics This
R4 Allocate
throughput
technological tools and creation of multidisciplinary
research in human-based settings
teams of experts
One example in this direction to significantly reduce animal
experimentation is provided by Europe and UK: for instance,
NC3Rs rates projects considering their scientific value as 50%
specific RFAs focused on non-animal/ and their contribution to the reduction of animal tests as the
R5 Create
remaining 50% of the final score (http://www.nc3rs.org.uk/
human-based research
funding). More directly, a dedicated call should be made for
complete and direct alternatives that offer new perspectives
and fundamentally ethical approach that do not involve animal
experimentation
Recognize the many types and growing applicability of nonanimal models in basic research. Dedicated funding should be
funding support for basic research
R6 Increase
allocated to high-risk high innovation studies, including the
studies to speed the discovery process
development of non-animal models for research in this area. Not
all projects need to be immediately translational in nature
There is an urgent need to increase funding for epidemiological
and clinical studies, focused on the impact of specific nutrition,
level of physical activity, and level of educational attainment
in the onset and progression of AD. Also, increase resources
for examining factors across multiple risk and ameliorating
variables including: environmental exposure, access to health
Increase funding to study risk factors and
care, sex and gender, ongoing social and cognitive engagement.
R7 evidence-based prevention approaches to slow Design intervention strategies in large scale cohorts. Dedicate
the progression of AD
resources to disseminate knowledge of known lifestyle factors
to the public at large as well as new incoming information.
Randomized clinical trials of individual dietary practices as
well as nutritional supplements. Begin with individuals who
have low or insufficient nutrient levels and for whom the highest beneficial effects have been observed (Morris, Tangney et
al. 2015)
Epidemiological studies addressing ethnic, cultural variations and implication of lifestyle risk factors would be highly
relevant both to smaller communities and lessons that can be
R8 Consider ethno-cultural factors
extended to the population at large.
Collaboration with epidemiological studies in other clinical domains, such as vascular research (Satizabal, Beiser et al. 2016)
will be critical for unmasking these complex relationships.
Abbreviations: CIRM, California Institute for Regenerative Medicine; NYSCF, New York Stem Cell Foundation;
CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography; FDG-PET, fluorodeoxyglucose-PET; RFAs, Requests for Applications.
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This envisioned paradigm and the application of
human-based models, in conjunction with large scale
randomized clinical trials and multi-dimensional -omics
readouts, will help revolutionize our knowledge of AD
pathology and etiology, contributing to the creation of a
more holistic perspective regarding AD in the context of
aging and lifestyle.
The NIH ADRD Research Summit, held at NIH
in February 2015, advocated for “a change in how the
academic, biopharmaceutical and government sectors
participating in Alzheimer’s research and therapy generate,
share and use knowledge to propel the development
of critically needed therapies” [127]. In particular,
the limitations of rodent models were highlighted
[127]. In line with this, we propose a list of practical
recommendations possibly suitable to guide current
funding priorities in AD research, addressing human
relevance. These recommendations, outlined in Table 3,
are meant to be applicable to the NIH as well as any AD
association subsidizing AD research.
The implementation of the proposed strategies
would necessarily require additional efforts to increase
general public awareness regarding AD pathology and
recognition of current failures in research efforts, and ways
to prevention. In particular, public initiatives and national
campaigns addressing the relevance of nutrition, cognitive
training, and physical activity as preventive strategies to
reduce the risk of AD and ameliorate AD symptoms, as the
ones recently undertaken [62, 63], should be encouraged
and supported.
Finally, it is important to implement education
and design curricula focused on currently available
human-based methods and readouts in both schools
and universities, to train new generations of scientists
competent in the field of alternatives to animal
experimentation, and well versed in the necessity and
power of multiscale human-based research approaches.
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